2009-2013年陕西省咸阳市肾综合征出血热疫苗免疫效果评价  

Evaluation on immune effect of bivalent vaccine of hemorrhagic fever with renal syndrome in Xianyang,Shaanxi,2009-2013

作　　者：李凤英 刘军礼 刘美宁 罗文瑞 马婷 邹利媛 马波 

机构地区：[1]咸阳市疾病预防控制中心,陕西咸阳712046

出　　处：《疾病监测》2014年第12期969-972,共4页Disease Surveillance

摘　　要：目的评价2009 2013年陕西省咸阳市双价肾综合征出血热(hemorrhagic fever with renal syndrome,HFRS)疫苗的免疫效果,为以疫苗接种为主的防控对策的制定提供更可靠的依据。方法随机选取100名监测对象,评价接种疫苗前、基础免疫后、加强接种后、加强接种1年等不同时间点,监测对象的抗体水平变化。结果基础免疫后监测对象HFRS抗体水平明显升高,加强接种后抗体水平达到最高峰,随后开始下降;HFRS抗体水平与地区、年龄关系不明显;基础免疫前抗体阳性率仅为4.26%(4/94),接种疫苗后,抗体阳性率达41.49%(39/94);加强免疫后抗体阳性率达61.70%(58/94);加强接种1年后,抗体阳性率为47.87%(49/94);经Mc Nemar检验,基础免疫的阳转率为38.89%(35/90),加强接种的阳转率可达到61.11%(55/90)。结论疫苗接种后出血热抗体水平和抗体阳性率明显升高,强化接种后下降,表明咸阳市采取疫苗接种仍是见效最快、最安全、效果最显著的防病措施。Objective To analyze the immune effect of bivalent vaccine of hemorrhagic fever with renal syndrome （HFRS） in Xianyang, Shaanxi province, and provide scientific evidence for the prevention strategy based on this vaccine. Methods A total of 100 subjects were selected to compare their antibody level before the vaccination, after basic vaccination, after booster vaccination and 1 year after booster vaccination. Results After basic vaccination, the overall antibody level to hantaan virus significantly increased, and reached its peak after booster vaccination, then begin to decline. Correlations between the antibody level and the area and age were not obvious. The antibody positive rate was 4. 26% before vaccination and 41.49% after basic vaccination. The antibody positive rate was 61.70% after booster vaccination and 47. 87% 1 year after booster vaccination. By McNemar test, the antibody seroconversion rate after basic vaccination was 38. 89% （35/90） and the antibody seroconversion rate reached 61.11% after booster vaccination （55/90）. Conclusion The antibody level and antibody-positive rate to hantaan virus increased obviously after bivalent HFRS vaccine immunization, indicating that the vaccine immunization is a fast, safe and effective measure for HFRS prevention and control.

关 键 词：肾综合征出血热 疫苗 免疫效果 

分 类 号：R392[医药卫生—免疫学]